VRTX Articles, Vertex Pharmaceuticals Incorporated - From 01/08/24

Vertex Pharmaceuticals (NASDAQ:VRTX) has outperformed the market over the past 15 years by 6.9% on an annualized basis producing an average annual ...

Vertex Pharmaceuticals (NASDAQ:VRTX) has outperformed the market over the past 20 years by 12.73% on an annualized basis producing an average annua...

Shares of Despegar.com, Corp. (NYSE: DESP) rose sharply during Wednesday’s session after the company raised its FY23 financial guidance. The ...

The FDA has approved Casgevy and Lyfgenia, representing the first cell-based gene therapies for sickle cell disease in patients 12 years ...

Vertex Pharmaceuticals (NASDAQ:VRTX) has outperformed the market over the past 15 years by 7.91% on an annualized basis producing an average annual...

Benzinga reviews this weekend's top stories covered by Barron's. Here are the articles investors need to read. In "Disney Now Faces Tw...

The Nasdaq 100 closed higher by 0.1% on Thursday. Investors, meanwhile, focused on some notable insider trades. When insiders sell shares, it could...

CRISPR Therapeutics AG (NASDAQ: CRSP) shares are trading higher Thursday after the company announced regulatory authorization of the first CRISPR/C...

The U.K. Medicines and Healthcare products Regulatory Agency (MHRA) has granted conditional marketing authorization for Casgevy (exagamglogene auto...

U.S. stocks are attempting to post the longest streak of consecutive positive sessions in over two years. As of midday trading in New York, both th...